| To view this email as a web page, click here.
|
 |
| |
| |
| Oncologists are busier than ever. They are pressed for time and must carefully balance their workload as they continue to learn the newest science and latest data to better treat their patients. |
| |
| So how do you ensure oncologists never miss your top abstracts and plenary sessions from the latest conferences? |
| |
| Rapid Readouts are packed with critical information covering various stages of trials and studies. In each segment, leading experts will: |
| |
 |
Review your abstracts/presentations from the latest conferences |
 |
Provide academic and community audiences with a timely look at data vital to improving patient care |
|
| |
| |
| Experience a Rapid Readout Today! |
| |
| Phase 1/2 Study Results of Liposomal Irinotecan and FOLFOX |
| |
| Zev A. Wainberg, MD, reviews the results from the phase 1/2 study of liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma. |
| |
 |
| |
| |
| Phase III PAOLA-1/ENGOT-ov25 Trial |
| |
| Bradley J. Monk MD, FACS, FACOG presents clinical data to support the standard systemic treatment for newly diagnosed advanced epithelial ovarian cancer. |
| |
|
| |
| |
Ensure oncologists never miss out on the top abstracts and plenary sessions from the latest conferences. Contact our team today to ensure your brand is positioned to win.
We look forward to being Your Link to Everything Oncology. |
| |
 |
|